Professor Andrew Wardley is a Consultant Medical Oncologist for breast cancer and Medical Director of the NIHR Manchester Clinical Research Facility at The Christie. Professor Wardley is also the Director for Systemic Anti-Cancer Therapy in Greater Manchester. He leads The Christie/Greater Manchester strategy to increase patient access to access to systemic anti-cancer therapy clinical trials across the conurbation.
Professor Wardley is Lead of the Clinical Research Group within the Manchester Breast Centre, of which he was a co-founder. His research interests include introducing new treatments in advanced breast cancer and translating clinical research into clinical practice. Professor Wardley has also been involved in major developments in HER2-positive breast cancer, including adjuvant trastuzumab (Herceptin) and pertuzumab (PERJETA) clinical development.